兰德桥公司

最新新闻

• Piper Sandler Maintains LandBridge(LB.US) With Hold Rating, Raises Target Price to $88
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  Piper Sandler Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $78
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 公司公告
  4: LB Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Garland J. Scott
  SEC · 2026/6/6
• Needham Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $68
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Clear Street Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $69
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  LB Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
  Dow Jones · 2026/8/24
• 评级变动
  Stifel Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $53
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Analysts' Opinions Are Mixed on These NA Stocks: LandBridge Company LLC Class A (LB) and Figma, Inc. Class A (FIG)
  TipRanks · 2026/8/6
• 公司公告
  4: LB Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Deep Track Biotechnology Master Fund, Ltd.
  SEC · 2026/8/4
• Eli Lilly Announces Detailed Results From TRIUMPH-2; TRIUMPH-2 Participants With Obesity And Type 2 Diabetes Taking Retatrutide 12 Mg Lost An Average Of 49.6 Lbs Over 80 Weeks; Retatrutide 12 Mg Leads To 60.8 Lb Weight Loss In BMI ≥35 Group; To Submit...
  Benzinga · 2026/9/30
• 评级变动
  Craig-Hallum Remains a Buy on LB Pharmaceuticals, Inc. (LBRX)
  TipRanks · 2026/8/12
• H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• Citi Initiates LandBridge(LB.US) With Hold Rating, Announces Target Price $86
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• 评级变动
  Goldman Sachs Maintains LandBridge(LB.US) With Buy Rating, Maintains Target Price $84
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 公司公告
  LB Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Lenz Robert A.
  SEC · 2026/3/11
• 公司公告
  LB Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Lenz Robert A.
  SEC · 2026/3/11
• 评级变动
  Piper Sandler Maintains LandBridge(LB.US) With Hold Rating, Maintains Target Price $80
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Clear Street Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $69
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  Analysts Offer Insights on NA Companies: AEVEX Corp. Class A (AVEX), LB Pharmaceuticals, Inc. (LBRX) and BETA Technologies, Inc. Class A (BETA)
  TipRanks · 2026/8/13
• 公司公告
  4: LB Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Lenz Robert A.
  SEC · 2026/6/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。